Updates and advances in the concept of gallbladder cancer treatment.
10.3760/cma.j.cn112139-20230131-00045
- VernacularTitle:胆囊癌治疗理念的更新与进展
- Author:
D M LIU
1
;
Q LI
1
Author Information
1. National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Tianjin Medical University Cancer Institute and Hospital,Key Laboratory of Cancer Prevention and Therapy,Department of Hepatobiliary Cancer, Liver Cancer Research Center, Tianjin 300060, China.
- Publication Type:Journal Article
- From:
Chinese Journal of Surgery
2023;61(9):749-752
- CountryChina
- Language:Chinese
-
Abstract:
The gallbladder is the most common site of tumor occurrence among biliary tract cancer. Gallbladder cancer accounts for approximately 0.6% of new cancers and 0.9% of cancer-related deaths. The risk factors identified for the development of gallbladder cancer include being female,>65 years of age, asymptomatic gallstone disease,and obesity. Surgical resection is the only curative treatment for early-stage gallbladder cancer, and some intermediate or advanced gallbladder cancers can be radically cured by extended resection. However, the extent of liver resection or lymph node dissection and whether to combine it with bile duct removal, revascularisation,and multiple organ resection remain somewhat controversial. After neoadjuvant treatment, up to a third of patients with locally advanced gallbladder cancer benefit from secondary surgical treatment. Only a small proportion of patients with gallbladder cancer at high risk for recurrence will benefit from postoperative adjuvant therapy. With the advent of different target-targeted drugs and the use of genetic tests in biliary tract cancer, targeted therapy and PD-1/PD-L1 inhibitors may become the new standard of care for gallbladder cancer and need to be further explored.
